Nanostructured lipid carrier containing CNS acting drug: Formulation, optimization and evaluation

Current Nanoscience

Volumn 7, Issue 6, 2011, Pages 1014-1027

  Alam, M Intakhab ^a   Baboota, Sanjula ^a   Ahuja, Alka ^a   Ali, Mushir ^a   Ali, Javed ^a   Sahni, Jasjeet Kaur ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

DLX; Encapsulation; Mucosal permeation; NLC; Sustained release; Zeta potential

Indexed keywords

DISPERSIONS; ENCAPSULATION; MORPHOLOGY; PARTICLE SIZE; PARTICLE SIZE ANALYSIS; PERMEATION; POLYDISPERSITY; SURFACE MORPHOLOGY; TARGETED DRUG DELIVERY; ZETA POTENTIAL;

BOX-BEHNKEN DESIGN; ENTRAPMENT EFFICIENCY; NANOSTRUCTURED LIPID CARRIER (NLC); NANOSTRUCTURED LIPID CARRIERS; POLYDISPERSITY INDICES; RESPONSE SURFACE METHODOLOGY; SUSTAINED RELEASE; ULTRA-SONICATION;

CONTROLLED DRUG DELIVERY;

DULOXETINE; NANOCARRIER; NANOSTRUCTURED LIPID CARRIER; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BRAIN; DRUG DOSAGE FORM COMPARISON; DRUG PENETRATION; DRUG STABILITY; FREEZE DRYING; IN VITRO STUDY; MATHEMATICAL MODEL; NANOFABRICATION; NONHUMAN; NOSE MUCOSA; PARTICLE SIZE; PRIORITY JOURNAL; RESPONSE SURFACE METHOD; SCANNING ELECTRON MICROSCOPY; SUSTAINED DRUG RELEASE; SUSTAINED RELEASE FORMULATION; SWINE; TARGET ORGAN; TRANSMISSION ELECTRON MICROSCOPY; ULTRASOUND; ZETA POTENTIAL;

EID: 82155192994     PISSN: 15734137     EISSN: 18756786     Source Type: Journal    
DOI: 10.2174/1573413711107061014     Document Type: Article

References (31)

1. Bymaster, F.P.; Dreshfield-Ahmad, L.J.; Threlkeld, P.G.; Shaw, J.L.; Thompson, L.; Nelson, D. L.; Hemrick-Luecke, S.K.; Wong, D.T. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology, 2001, 25(6), 871-880.
2. Jain, A.; Jain, S.K. Drug targeting to the brain - a review. Curr. Nanosci., 2011, 7(1), 21-36.
3. Alam, M.I.; Beg, S.; Samad, A.; Baboota, S.; Kohli, K.; Ali, J.; Ahuja, A.; Akbar, M. Strategy for effective brain drug delivery. Eur. J. Pharm. Sci., 2010, 40, 385-403.
4. ®) for oral drug delivery. Drug Dev. Ind. Pharm., 2008, 34, 1394-1405.
5. Yang, S.; Zhu, J.; Lu, Y.; Liang, B.; Yang, C. Body distribution of camp-tothecin solid lipid nanoparticles after oral administration. Pharm. Res., 1999, 16(5), 751-757.
6. Hunt, C.; Tsang, S. Tocopherol retards auto-oxidation and prolongs the shelf-life of liposomes. Int. J. Pharm., 1981, 8, 101-110.
7. Wong, M.; Thompson, T. Aggregation of dipalmitoylphosphatidylcholine vesicles. Biochemistry, 1982, 21, 4133-4139.
8. Muller, R.H.; Radtke, M.; Wissing, S.A. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv. Drug Deliv. Rev., 2002, 54, S131-S155.
9. Freitas, C.; Muller, R.H. Correlation between long-term stability of solid lipid nanoparticles (SLNTM) and crystallinity of the lipid phase. Eur. J. Pharm. Biopharm., 1999, 47, 125-132.
10. Yang, L.; Zhang, H.; Fawcett, J.P.; Mikov, M.; Tucker, I.G. Effect of bile salts on the transport of morphine-6-glucuronide in rat brain endothelial cells. J. Pharm. Sci., 2010, 100(4), 1516-1524.
11. Han, F.; Li, S.; Yin, R.; Liu, H.; Xu, L. Effect of surfactants on the formation and characterization of a new type of colloidal drug delivery system: nanostructured lipid carriers. Colloids Surf. A: Physicochem. Eng. Asp., 2008, 315, 210-216.
12. Liu, C.H.; Wu, C.T. Optimization of nanostructured lipid carriers for lutein delivery. Colloids Surf. A: Physicochem. Eng. Asp., 2010, 353, 149-156.
13. Souto, E.B.; Mehnert, W.; Muller, R.H. Polymorphic behaviour of Compritol-888 ATO as bulk lipid and as SLN and NLC. J. Microencapsul., 2006, 23(4), 417-433.
14. Westesen, K.; Siekmann, B. Comparison of parenteral lipid emulsions and solid lipid nanoparticles. Eur. J. Pharm. Biopharm., 1994, 40, 35S.
15. Zhang, W.; Fang, X.L. Significant role of poloxamer in drug transport across blood-brain barrier. Yao Xue Xue Bao, 2008, 43(9), 890-897.
16. Liu, K.; Sun, J.; Wang, Y.; He, Y.; Gao, K.; He, Z. Preparation and characterization of 10-hydroxycamptothecin loaded nanostructured lipid carriers. Drug Dev. Ind. Pharm., 2008, 34, 465-471.
17. Ferreira, S.L.C.; Bruns, R.E.; Ferreira, H.S.; Matos, G.D.; David, J.M.; Brandao, G.C.; da Silva, E.G.P.; Portugal, L.A.; Dos Reis, P.S.; Souza, A.S.; Dos Santos, W.N.L. Box-Behnken design: An alternative for the optimization of analytical methods. Anal. Chim. Acta, 2007, 597(2), 179-186.
18. Mehnert, W.; Mader, K. Solid lipid nanoparticles production, characteriza-tion and applications. Adv. Drug Deliv. Rev., 2001, 47, 165-196.
19. Zhang, X.; Liu, J.; Qiao, H.; Liu, H.; Ni, J.; Zhang, W.; Shi, Y. Formulation optimization of dihydroartemisinin nanostructured lipid carrier using response surface methodology. Powder Tech., 2010, 197, 120-128.
20. Hou, D.; Xie, C.; Huang, K.; Zhu, C. The production and characteristics of solid lipid nanoparticles (SLNs). Biomaterials, 2003, 24(10), 1781-1785.
21. Hu, F.Q.; Jiang, S.P.; Du, Y.Z.; Yuan, H.; Ye, Y.Q.; Zeng, S. Preparation and characteristics of monostearin nanostructured lipid carriers. Int. J. Pharm., 2006, 314, 83-89.
22. Yang, S.C.; Zhu, J.B. Preparation and characterization of camptothecin solid lipid nanoparticles. Drug Dev. Ind. Pharm., 2002, 28(3), 265-274.
23. Gref, R.; Minamitake, Y.; Peracchia, M.T.; Trebetskoy, V.S.; Torchilin, V.P.; Langer, R. Biodegradable long-circulating polymeric nanospheres. Science, 1994, 263, 1600-1603.
24. Lin, X.; Li, X.; Zheng, L.; Yu, L.; Zhang, Q.; Liu, W. Preparation and characterization of monocaprate nanostructured lipid carriers. Colloids Surf. A: Physicochem. Eng. Asp., 2007, 311, 106-111.
25. Cheboyina, S.; Wyandt, C.M. Wax-based sustained release matrix pellets prepared by a novel freeze pelletization technique. II. In vitro drug release studies and release mechanisms. Int. J. Pharm., 2008, 359, 167-173.
26. Abdel-Mottaleb, M.M.A.; Neumann, D.; Lamprecht, A. In vitro drug release mechanism from lipid nanocapsules (LNC). Int. J. Pharm., 2010, 390, 208-213.
27. Souto, E.B.; Wissing, S.A.; Barbosa, C.M.; Muller, R.H. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int. J. Pharm., 2004, 278, 71-77.
28. Teeranachaideekul, V.; Souto, E.B.; Junyaprasert, V.B.; Muller, R.H. Cetyl palmitate-based NLC for topical delivery of Coenzyme Q10-Development, physicochemical characterization and in vitro release studies. Eur. J. Pharm. Biopharm., 2007, 67, 141-148.
29. Langer, R.S.; Peppas, A. Present and future applications of biomaterials in controlled drug delivery systems. Biomaterials, 1981, 2, 201-214.
30. Bhaskar, K.; Anbu, J.; Ravichandiran, V.; Venkateswarlu, V.; Rao, Y.M. Lipid nanoparticles for transdermal delivery of flurbiprofen: formulation, in vitro, ex vivo and in vivo studies. Lipids Health Dis., 2009, 8, 6.
31. Venkateswarlu, V.; Manjunath, K. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J. Control. Release, 2004, 24, 627-638.